| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02399917 Details | 2019-09-24 Interventional | 2 | 36 | Azacitidine Leukemia Leukemia, Biphe… Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Acute Biphenoty… Acute Myeloid L… Recurrent Acute… Refractory Acut… | This study was terminated early due to response rates not meeting the anticipated minimum of
30%. - | |||
| NCT01874236 Details | 2019-09-24 Interventional | 4 | 28 | Bupivacaine Arthralgia SI Joint Pain | Data could not be interpreted. Re-design efforts failed. - | |||
| NCT01873495 Details | 2019-09-24 Interventional | 2 | 7 | Homoharringtoni… Leukemia, Myelo… Leukemia, Myelo… Acute Myelogeno… | - Accrual was halted early due to the inability of 30% of subjects to complete the intended consolidation and maintenance. | |||
| NCT00727194 Details | 2019-09-24 Interventional | 2 | [1 Refs] | 14 | Eculizumab Muscle Weakness Myasthenia Grav… | - Small sample size limited ability to detect intercohort differences. Carryover effect from Treatment Period (TP) 1 warrants cautious interpretation of TP 2 data. Study terminated early; 13 patients received eculizumab or placebo in TP2. | ||
| NCT00078897 Details | 2019-09-24 Interventional | 3 | 1621 | Selenium Adenomatous Pol… Colorectal Neop… Polyps Precancerous Co… Adenomatous Col… Colorectal Canc… Precancerous Co… | Concluded - Terminated by PI - | |||
| NCT03315052 Details | 2019-09-23 Interventional | 4 | [1 Refs] | 0 | Budesonide Mycophenolic Ac… Prednisone Tacrolimus Acute Cellular … Liver Transplan… | Delay in IRB approval - | ||
| NCT02618668 Details | 2019-09-23 Interventional | 2 | 90 | Ketamine Propofol Cholangitis Pancreatitis | - - | |||
| NCT01964755 Details | 2019-09-23 Interventional | 2 | 6 | Doxorubicin Formyltetrahydr… Hydroxyurea Leucovorin Levoleucovorin Methotrexate Rituximab Tetrahydrofolat… Zidovudine Epstein-Barr Vi… Hodgkin Disease Lymphoma Lymphoma, Non-H… Lymphoprolifera… Virus Diseases Epstein Barr Vi… Epstein Barr Vi… Post-Transplant… | Investigator Decision - | |||
| NCT03456661 2014-002589-56 Details | 2019-09-20 Interventional | 4 | - | Dexmedetomidine Levobupivacaine Breast Cancer Mastectomy, Mod… | The surgical approach has changed. - | |||
| NCT02551055 2015-001032-38 Details | 2019-09-20 Interventional | 1 | 32 | Docetaxel Paclitaxel Serabelisib Adenocarcinoma Advanced and Me… | Business Decision; No Safety Or Efficacy Concerns. Due to the early termination of the study, the pharmacokinetic data collected was not processed further. Therefore, the planned secondary endpoints of PK summary statistics are not reported. | |||
| NCT01599754 Details | 2019-09-20 Interventional | 3 | 724 | Axitinib Carcinoma, Rena… Kidney Neoplasm… Clear Cell Rena… | Primary endpoint did not reach statistical significance - | |||
| NCT00140894 Details | 2019-09-20 Interventional | 4 | - | Rofecoxib Adenomatous Pol… Colorectal Neop… Nasopharyngeal … | - - | |||
| NCT03788889 Details | 2019-09-19 Interventional | 4 | 0 | Ketamine Lorazepam Phenobarbital Substance Withd… Syndrome Alcohol Withdra… | internal practice and policy limitations including time commitment / workflow issues - | |||
| NCT03766607 Details | 2019-09-19 Interventional | 2 | 0 | Paclitaxel Ramucirumab Trastuzumab Stomach Neoplas… Gastric Cancer | Competing other studies - | |||
| NCT03286582 Details | 2019-09-19 Interventional | 2 | 10 | Clobetasol Pemphigoid, Bul… Bullous Pemphig… | Terminated with partial enrollment completed - | |||
| NCT02769169 Details | 2019-09-19 Interventional | 2/3 | [6 Refs] | 5 | Ranibizumab Polypoidal Chor… Vascular Diseas… | study protocol changed - | ||
| NCT01202721 Details | 2019-09-18 Interventional | 3 | 85 | Atenolol Telmisartan Aortic Valve Di… Bicuspid Aortic… Heart Diseases Cardiac Disease | Terminated early due to lack of study feasibility and poor patient recruitment - | |||
| NCT03978494 2018-002672-40 Details | 2019-09-17 Interventional | 1 | 0 | Tacrolimus Kidney Transpla… | company decision - | |||
| NCT03110575 Details | 2019-09-17 Interventional | 3 | 189 | Cyclobenzaprine Stress Disorder… PTSD | Stopped early due to inadequate separation on primary efficacy endpoint in the lead-in HONOR
study, TNX-CY-P301 - | |||
| NCT03062540 Details | 2019-09-17 Interventional | 3 | 358 | Cyclobenzaprine Stress Disorder… PTSD | Stopped early due to inadequate separation on primary efficacy endpoint at Week 12 according to
Interim Analysis conducted on the first 274 (50%) patients. - |